恩华药业 (002262.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

17.5x

EV/EBITDA

14.9x

Market Cap

CNY 22.20B

MomentumView details →

1D Return

−0.46%

YTD Return

−6.51%

RSI (14)

56.3

ValuationView details →

P/E (Fwd)

17.5x

EV/EBITDA

14.9x

Market Cap

CNY 22.20B

RSI (14)

56.3

MomentumView details →

1D Return

−0.46%

YTD Return

−6.51%

ProfitabilityView details →

Gross Margin

71.17%

Net Margin

17.87%

EBITDA Margin

23.93%

ROE (TTM)

12.83%

ROA (TTM)

11.14%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

+2.73%

EPS YoY

−9.65%

FCF YoY

−13.04%

Revenue CAGR 3Y

+11.20%

EPS CAGR 3Y

+5.67%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.42

EPS Surprise

13.51%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.45

Avg Surprise (4Q)

13.51%

Rev Surprise

0.99%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

5.69x

Quick Ratio

5.12x

Div Yield

1.77%

Div Rate

CNY 0.40

Div Growth 1Y

+11.11%

Financials snapshotView financials →

Revenue (TTM)

6.01B

Net Income (TTM)

1.07B

Op. CF (TTM)

916.95M

Next earningsOct 22, 2026 →

Latest newsMore news →

Nhwa Pharmaceutical obtained the Drug Registration Certificate for Brexpiprazole tablets approved by the National Medical Products Administration; the drug is used to treat adult schizophrenia.8d ago

Similar companies

沃尔核材002130.SZ 创世纪300083.SZ 许继电气000400.SZ 机器人300024.SZ 杭氧股份002430.SZ 科华数据002335.SZ Find similar companies →

Latest newsMore news →

Nhwa Pharmaceutical obtained the Drug Registration Certificate for Brexpiprazole tablets approved by the National Medical Products Administration; the drug is used to treat adult schizophrenia.8d ago